The agreement includes an option for bioMérieux to use Affymetrix GeneChip® technology in other cancer areas.
Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
Chinese Academy of Medical Sciences and bioMerieux join resources to fight emerging pathogens
11 März, 2005
The Chinese Academy of Medical Sciences and bioMérieux announce that they have signed a strategic teaming agreement, aiming at initiating R&D projects in the fields of emerging pathogens. The aim of the project, signed on March 10th, is the creation of a joint Research Lab in Beijing, interacting with Chinese Academy of Medical Sciences.
B·R·A·H·M·S AG and bioMérieux SA sign a non-exclusive agreement on the use of Procalcitonin
01 März, 2005
B·R·A·H·M·S AG and bioMérieux SA have announced the signature of a non-exclusive agreement on the use of Procalcitonin as a diagnostic marker for severe bacterial infections
bioMérieux innovates in food quality testing
31 Januar, 2005
bioMérieux launches VITEK® 2 Compact to complete its VITEK 2 range
06 Januar, 2005
A world leader in the field of in vitro diagnostics, bioMérieux SA (Euronext: FR0010096479 – BIM) completes its VITEK® 2 range of automated microbial identification and susceptibility testing systems through the launch of VITEK 2 Compact. VITEK 2 Compact is powered by the Advanced Expert System (AES™) software, which validates and interprets susceptibility test results, and detects antibiotic resistance mechanisms.
bioMérieux acquires an option to license Applied NeuroSolutions’ Technology to diagnose Alzheimer’s disease
15 Dezember, 2004
bioMérieux SA (Euronext: FR0010096479 – BIM) , announces today that it signed a non-exclusive agreement with Applied Neurosolutions granting bioMérieux SA an option to assess Applied Neurosolutions’ technology for the diagnosis of Alzheimer’s disease.
bioMérieux reveals VIDIA, its new automated immunoanalyser, in Paris at the Journées Internationales de Biologie
05 November, 2004
A major player in the in vitro diagnostics marketplace, bioMérieux announces the first official presentation of its new fully automated immunoanalyser, VIDIA®. The system will be presented to healthcare professionals at the Journées Internationales de Biologie held in Paris from November 4 - 6, 2004.
bioMérieux to assess potential of PlasmAcute® Technology for tuberculosis testing
25 Oktober, 2004
Novel Diagnostics ASA and bioMérieux announced today that they have signed an agreement that gives bioMérieux access to patented PlasmAcute® acute phase antibody detection technology for use in the field of tuberculosis detection.
bioMérieux signs New Agreements with Gen-Probe
10 Oktober, 2004
bioMérieux receives a $ 1 million license fee for access to its markers for blood clotting disorders. bioMérieux to give Gen-Probe an option for the access to bioMérieux NUCLISENS EASYQ® platform. bioMérieux Gains Access to ribosomal RNA markers to support its future growth in molecular biology.
bioMérieux innovates further in the fight against AIDS
27 September, 2004
A major player in the field of in vitro diagnostics, bioMérieux confirms its constant commitment to the fight against AIDS with the launch of two new advanced 4th generation tests for HIV screening. VIDAS® HIV DUO ULTRA and VIDAS HIV DUO QUICK, developed for use on the automated VIDAS immunoanalysis system, are ultra-sensitive tests, providing even earlier detection of HIV infection.